ClinicalTrials.gg
RecruitingNCT07479732Updated Mar 18, 2026

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

A Phase 1/2 interventional study of Liposomal Irinotecan and Apatinib in arm1 in Osteosarcoma and Osteosarcoma Metastatic, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Peking University People's Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Osteosarcoma by Peking University People's Hospital — 5 open to participants now, 7 under way, none of them phase 3. Osteosarcoma · Peking University People's Hospital.

Planned enrollment
6th of 12
56 · median 56
Started
2026
the only one that year
Phase 1/2
3 of 26
2 open now
Registered
25th of 26
by date

Among the 26 studies in Osteosarcoma by Peking University People's Hospital, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 1/2, and was the 25th registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

5 of the 26 studies in Osteosarcoma by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Osteosarcoma by Peking University People's Hospital, or all of them as a file.
02

Study summary

In advanced osteosarcoma where traditional chemotherapy has failed, the multi-targeted tyrosine kinase inhibitor apatinib has become a mainstream systemic treatment option in China. However, for patients with a high tumor burden or extra-pulmonary lesions, these drugs are prone to secondary resistance, necessitating combination with chemotherapy for more effective comprehensive control. Liposomal irinotecan, a newly approved topoisomerase inhibitor, exhibits lower toxicity compared to traditional irinotecan and is one of the second-line chemotherapy agents for osteosarcoma, making it a suitable candidate for combination therapy with apatinib.

The primary objective of this study is to determine the optimal regimen of apatinib combined with liposomal irinotecan injection, while the secondary objective is to evaluate the safety and efficacy of this combination in patients with refractory osteosarcoma who have progressed after second-line chemotherapy.

Read the detailed description

Osteosarcoma is the most common primary malignant bone tumor in adolescents and young adults. Although multimodal treatment including surgery and multi-agent chemotherapy has improved survival for patients with localized disease, the prognosis of patients with recurrent or metastatic osteosarcoma remains poor.

Targeting tumor angiogenesis has emerged as a promising therapeutic strategy for osteosarcoma. Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively inhibits VEGFR-2 and has demonstrated clinical activity in advanced osteosarcoma in previous studies.

Irinotecan is a topoisomerase I inhibitor with antitumor activity in several malignancies. Liposomal irinotecan is a nanoliposomal formulation that improves the pharmacokinetic profile and intratumoral delivery of irinotecan, potentially enhancing its antitumor effect.

This investigator-initiated study is designed to evaluate the safety, tolerability, and preliminary efficacy of apatinib combined with liposomal irinotecan in patients with recurrent or refractory osteosarcoma. Patients will receive oral apatinib daily in combination with intravenous liposomal irinotecan administered every two weeks until disease progression, unacceptable toxicity, or withdrawal of consent.

The primary objective is to evaluate the safety and tolerability of the combination therapy. Secondary objectives include evaluation of antitumor activity such as objective response rate, progression-free survival, and overall survival.

03

Conditions studied

  • Osteosarcoma
  • Osteosarcoma Metastatic

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject or their legal representative must sign a written form prior to enrollment.
  2. Diagnosis of osteosarcoma confirmed by histopathology. Pathological confirmation is mandatory for localized tumors and isolated pulmonary lesions; it is not required for multiple pulmonary .
  3. Disease progression after standard, adequate and second-line chemotherapy regimens for osteosarcoma, or progression within 6 months of stopping such therapy.
  4. At least one measurable target lesion according to version 1.1 criteria.
  5. Performance Status score of 0 or 1, with an expected survival of ≥3 months.
  6. Recovery from prior therapies: all side effects (except alopecia) must have resolved to Grade 1 or lower per version 5.0.
  7. Adequate organ function as indicated by the following peripheral blood counts and serum biochemistry results
  8. Women of must agree to use effective (e.g., intrauterine device, oral contraceptives, or condoms) during the study and for 6 months after study completion; they must have a negative serum or urine pregnancy test within 7 days prior to study enrollment and must not be breastfeeding. Male participants must agree to use effective contraception or have undergone surgical sterilization during the study and for 6 months after its completion.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with apatinib.
  2. Prior use of irinotecan or other analogues of topoisomerase inhibitors.
  3. Known allergic reactions, , or intolerance to apatinib, liposomal irinotecan, or any of their .
  4. Within 3 weeks after the last dose of any prior therapy, including systemic cytotoxic drug therapy, targeted therapy, radiotherapy, immunotherapy, or any other therapy.
  5. Diagnosis of other within the past 3 years, except for adequately treated cutaneous basal cell carcinoma, carcinoma in situ of the cervix, or breast cancer that has undergone radical resection and remained disease-free for >3 years.
  6. Patients with known , spinal cord compression, carcinomatous meningitis, or those with imaging evidence of or unstable brain lesions detected by CT or MRI during screening.
  7. Patients with symptomatic serous cavity effusions (e.g., pleural effusion, ascites, or pericardial effusion) requiring surgical intervention.
  8. Uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg despite optimal medical therapy).
  9. Other poorly controlled diseases.
  10. Participation in clinical trials of other antitumor drugs within the 4 weeks prior to enrollment.
  11. Treatment with strong inhibitors within 7 days prior to study participation, or treatment with strong CYP3A4 inducers within 12 days prior to study participation.
  12. Patients currently receiving concurrent antitumor therapy.
  13. Patients with target lesions having previously received radiotherapy, but without subsequent progression.
  14. Patients who have received any vaccination during the treatment period, or have received an adenovirus-based vaccine within 4 weeks.
  15. Lactating women.
  16. Any condition that, in the investigator's judgment, may compromise the subject's well-being or ability to comply with or fulfill the study requirements.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Apatinib + Liposomal Irinotecan

    Patients receive apatinib orally once daily in combination with liposomal irinotecan administered intravenously every week until disease progression or unacceptable toxicity.

    Drug: Liposomal Irinotecan · Drug: Apatinib in arm1

Interventions

  • DrugIrinotecanStudies of IrinotecanIrinotecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous liposomal irinotecan administered on Day 1, 8, and 15 of each 3-week cycle.

  • DrugApatinib in arm1

    Oral VEGFR-2 tyrosine kinase inhibitor administered in combination with liposomal irinotecan.

06

What researchers measure

Primary outcomes

  1. Recommended Phase II Dose (RP2D)

    Determination of the recommended phase II dose based on dose-limiting toxicity (DLT) observed during the first two cycles (6 weeks).

    Time frame: 6 weeks

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Every 6 weeks up to 24 months

  2. Progression-Free Survival (PFS)

    Time frame: From treatment initiation until disease progression or death, up to 24 months

  3. Overall Survival,OS

    Time frame: From treatment initiation until death from any cause, up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015 Sep 20;33(27):3029-35. doi: 10.1200/JCO.2014.59.4895. Epub 2015 Aug 24. PubMed 26304877 ↗
  • Xie L, Xu J, Sun X, Tang X, Yan T, Yang R, Guo W. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. Oncologist. 2019 Jul;24(7):e542-e550. doi: 10.1634/theoncologist.2018-0542. Epub 2018 Dec 17. PubMed 30559126 ↗
  • Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. PubMed 26615328 ↗
  • Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007 Feb;48(2):132-9. doi: 10.1002/pbc.20697. PubMed 16317751 ↗
  • Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3. Epub 2018 Nov 23. PubMed 30477937 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 33 phase 1/2 interventional studies under Osteosarcoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 92. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 18, 2026
StartEst.
Mar 5, 2026
Primary completionEst.
Mar 5, 2027
CompletionEst.
Jan 1, 2028
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07479732
Responsible party
Xie Lu (associate chief physician, Peking University People's Hospital) — Principal investigator
First posted
Mar 18, 2026
Start date
Mar 5, 2026 (estimated)
Primary completion
Mar 5, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Mar 18, 2026

Study contacts

Xie Lu LuXie
Contact
xie.lu@hotmail.com
86+13401044719

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irinotecan

Start the discussion